Novartis' Skin Cancer Therapy Approved In Europe
This article was originally published in Scrip
Executive Summary
Novartis AG's skin cancer drug Odomzo (sonidegib) has been approved in the EU for use in patients with locally advanced basal cell carcinoma (LaBCC).